Cargando…

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates

Ibrexafungerp is a novel triterpenoid antifungal that inhibits glucan synthase and thus fungal cell wall synthesis. We examined the in vitro activity against contemporary clinical yeast, investigated inter-laboratory and intra-laboratory variability, suggested wild-type upper-limit values (WT-UL), a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jørgensen, Karin M., Astvad, Karen M. T., Hare, Rasmus K., Arendrup, Maiken C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605171/ https://www.ncbi.nlm.nih.gov/pubmed/36294671 http://dx.doi.org/10.3390/jof8101106

Ejemplares similares

EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
por: Jørgensen, Karin Meinike, et al.
Publicado: (2019)

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Spectrophotometric detection of azole-resistant Aspergillus fumigatus with the EUCAST broth microdilution method: is it time for automated MIC reading of EUCAST antifungal susceptibility testing of Aspergillus species?
por: Meletiadis, Joseph, et al.
Publicado: (2022)

Increasing Terbinafine Resistance in Danish Trichophyton Isolates 2019–2020
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Correction: Astvad et al. Increasing Terbinafine Resistance in Danish Trichophyton Isolates 2019–2020. J. Fungi 2022, 8, 150
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Evaluation of MIC Strip Isavuconazole Test for Susceptibility Testing of Wild-Type and Non-Wild-Type Aspergillus fumigatus Isolates
por: Arendrup, Maiken Cavling, et al.
Publicado: (2016)

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
por: Ghannoum, Mahmoud, et al.
Publicado: (2020)

In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies
por: Rivero-Menendez, Olga, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Comparison between EUCAST Broth Microdilution and MIC Strip Test in Defining Isavuconazole In Vitro Susceptibility against Candida and Rare Yeast Clinical Isolates
por: Calvo, Maddalena, et al.
Publicado: (2023)

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications
por: Rogers, Thomas R, et al.
Publicado: (2022)

Implementation of Isavuconazole in a Fluorescence-Based High-Performance Liquid Chromatography Kit Allowing Simultaneous Detection of All Four Currently Licensed Mold-Active Triazoles
por: Jørgensen, René, et al.
Publicado: (2017)

Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance
por: Jørgensen, Karin Meinike, et al.
Publicado: (2021)

Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022)

Azole resistance in Aspergillus fumigatus. The first 2‐year's Data from the Danish National Surveillance Study, 2018–2020
por: Risum, Malene, et al.
Publicado: (2022)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Update 2016–2018 of the Nationwide Danish Fungaemia Surveillance Study: Epidemiologic Changes in a 15-Year Perspective
por: Risum, Malene, et al.
Publicado: (2021)

Comparison of the Micronaut-AM System and the EUCAST Broth Microdilution Reference Method for MIC Determination of Four Antifungals against Aspergillus fumigatus
por: Gyurtane Szabo, Nikolett, et al.
Publicado: (2023)

In Vivo Selection of a Unique Tandem Repeat Mediated Azole Resistance Mechanism (TR(120)) in Aspergillus fumigatus cyp51A, Denmark
por: Hare, Rasmus K., et al.
Publicado: (2019)

Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study
por: Haldorsen, Bjørg, et al.
Publicado: (2018)

Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study
por: Haldorsen, Bjørg, et al.
Publicado: (2018)

Instruction videos from EUCAST
Publicado: (2020)

In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order
por: Arendrup, Maiken Cavling, et al.
Publicado: (2015)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

342. Multicenter Evaluation of Fosfomycin MIC Results for Enterobacterales Using EUCAST V11 Breakpoints (i.v. and oral for uncomplicated UTI only, E. coli) on MicroScan Dried Gram Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2022)

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
por: Daraskevicius, Justinas, et al.
Publicado: (2022)

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
por: Phillips, Nancy A, et al.
Publicado: (2023)

Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility
por: Kahlmeter, Gunnar, et al.
Publicado: (2020)

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
por: Quindós, Guillermo, et al.
Publicado: (2022)

Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes
por: Papadimitriou-Olivgeris, Matthaios, et al.
Publicado: (2020)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
por: Jallow, Sabelle, et al.
Publicado: (2021)

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022)

Azole-Resistant Aspergillus fumigatus Among Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR(34)/L98H
por: Risum, Malene, et al.
Publicado: (2020)

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
por: Nyirjesy, Paul, et al.
Publicado: (2021)

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
por: Goje, Oluwatosin, et al.
Publicado: (2023)

Disinfection trials with terbinafine‐susceptible and terbinafine‐resistant dermatophytes
por: Skaastrup, Kristoffer Nagy, et al.
Publicado: (2022)

New definitions of susceptibility categories EUCAST 2019: clinic application
por: Díaz, Sandra G. Nabal, et al.
Publicado: (2022)

The Influence of Medium Composition on EUCAST and Etest Antifungal Susceptibility Testing
por: Vahedi-Shahandashti, Roya, et al.
Publicado: (2023)

Time to switch from CLSI to EUCAST? A Southeast Asian perspective
por: Cusack, T.P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f86rtve22d2m7phlv5hg3r1nt5